Reproducibility of CSF quantitative culture methods for estimating rate of clearance in cryptococcal meningitis

Medical Mycology

Volumn 54, Issue 4, 2016, Pages 361-369

  Dyal, Jonathan ^a,b   Akampurira, Andrew ^b,c   Rhein, Joshua ^a,b   Morawski, Bozena M ^a   Kiggundu, Reuben ^b   Nabeta, Henry W ^b   Musubire, Abdu K ^a,b,c   Bahr, Nathan C ^a   Williams, Darlisha A ^a,b   Bicanic, Tihana ^d   Larsen, Robert A ^e   Meya, David B ^a,b,c   Boulware, David R ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

^b MAKERERE UNIVERSITY   (Uganda)

^c MAKERERE UNIVERSITY COLLEGE OF HEALTH SCIENCES   (Uganda)

^d ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^e UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Accuracy; Cryptococcus; Culture; HIV AIDS; Meningitis; Methodology

Indexed keywords

AMPHOTERICIN; AMPHOTERICIN B; ANTIRETROVIRUS AGENT; FLUCONAZOLE; SERTRALINE; ANTIFUNGAL AGENT;

ADD ON THERAPY; ADULT; ANTIRETROVIRAL THERAPY; ARTICLE; CD4 LYMPHOCYTE COUNT; CELL CULTURE TECHNIQUE; CEREBROSPINAL FLUID; CEREBROSPINAL FLUID CULTURE; COLONY FORMING UNIT; CRYPTOCOCCAL MENINGITIS; DISEASE CLEARANCE; DISEASE SEVERITY; DOSE CALCULATION; FEMALE; FILOBASIDIELLA; FOLLOW UP; FUNGICIDAL ACTIVITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LEUKOCYTE COUNT; LIMIT OF DETECTION; LUMBAR PUNCTURE; MAJOR CLINICAL STUDY; MALE; MEASUREMENT ACCURACY; METHODOLOGY; PHASE 2 CLINICAL TRIAL (TOPIC); PREDICTIVE VALUE; REPRODUCIBILITY; UGANDA; AIDS-RELATED OPPORTUNISTIC INFECTIONS; MENINGITIS, CRYPTOCOCCAL; MICROBIOLOGY; MYCOLOGY; PROCEDURES; PROSPECTIVE STUDY; SEVERITY OF ILLNESS INDEX; STANDARDS;

ADULT; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTIFUNGAL AGENTS; CEREBROSPINAL FLUID; FEMALE; HUMANS; LIMIT OF DETECTION; MALE; MENINGITIS, CRYPTOCOCCAL; MYCOLOGY; PROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX;

EID: 84996769232     PISSN: 13693786     EISSN: 14602709     Source Type: Journal    
DOI: 10.1093/mmy/myv104     Document Type: Article

References (17)

1. Park BJ, Wannemuehler KA, Marston BJ et al. Estimation of the current global burden of cryptococcal meningitis among persons living with HIV/AIDS. AIDS 2009; 23: 525-530.
2. Durski KN, Kuntz KM, Yasukawa K et al. Cost-effective diagnostic checklists for meningitis in resource-limited settings. J Acquir Immune Defic Syndr 2013; 63: e101-108.
3. Bicanic T, Muzoora C, Brouwer AE et al. Independent association between rate of clearance of infection and clinical outcome of HIV associated cryptococcal meningitis: analysis of a combined cohort of 262 patients. Clin Infect Dis 2009; 49: 702-709.
4. Jarvis JN, Bicanic T, Loyse A et al. Determinants of mortality in a combined cohort of 501 patients with HIV-associated Cryptococcal meningitis: implications for improving outcomes. Clin Infect Dis 2014; 58: 736-745.
5. Bicanic T, Wood R, Meintjes G et al. High-dose amphotericin B with flucytosine for the treatment of cryptococcal meningitis in HIV-infected patients: a randomized trial. Clin Infect Dis 2008; 47: 123-130.
6. Brouwer AE, Rajanuwong A, Chierakul W et al. Combination antifungal therapies for HIV-associated cryptococcal meningitis: a randomised trial. Lancet 2004; 363: 1764-1767.
7. Bicanic T, Meintjes G, Wood R et al. Fungal burden, early fungicidal activity, and outcome in cryptococcal meningitis in antiretroviral-naive or antiretroviral-experienced patients treatedwith amphotericin B or fluconazole. Clin Infect Dis 2007; 45: 76-80.
8. Longley N, Muzoora C, Taseera K et al. Dose response effect of high-dose fluconazole for HIV-associated cryptococcal meningitis in southwestern Uganda. Clin Infect Dis 2008; 47: 1556-1561.
9. Muzoora CK, Kabanda T, Ortu G et al. Short course amphotericin B with high dose fluconazole for HIV-associated cryptococcal meningitis. J Infect 2012; 64: 76-81.
10. Loyse A, Wilson D, Meintjes G et al. Comparison of the early fungicidal activity of high-dose fluconazole, voriconazole, and flucytosine as second-line drugs given in combination with amphotericin B for the treatment of HIV-associated cryptococcal meningitis. Clin Infect Dis 2012; 54: 121-128.
11. Jarvis JN, Meintjes G, Rebe K et al. Adjunctive interferongamma immunotherapy for the treatment of HIV-associated cryptococcal meningitis: a randomized controlled trial. AIDS 2012; 26: 1105-1113.
12. Boulware DR, Rolfes MA, Rajasingham R et al. Multisite validation of cryptococcal antigen lateral flow assay and quantification by laser thermal contrast. Emerg Infect Dis 2014; 20: 45-53.
13. Robinson PA, Bauer M, Leal MA et al. Early mycological treatment failure in AIDS-associated cryptococcal meningitis. Clin Infect Dis 1999; 28: 82-92.
14. Chang CC, Dorasamy AA, Gosnell BI et al. Clinical and mycological predictors of cryptococcosis-associated immune reconstitution inflammatory syndrome. AIDS 2013; 27: 2089-2099.
15. Kabanda T, Siedner MJ, Klausner JD et al. Point-of-care diagnosis and prognostication of cryptococcal meningitis with the cryptococcal antigen lateral flow assay on cerebrospinal fluid. Clin Infect Dis 2014; 58: 113-116.
16. Williams DA, Kiiza T, Kwizera R et al. Evaluation of fingerstick cryptococcal antigen lateral flow assay in HIV-infected persons: a diagnostic accuracy study. Clin Infect Dis 2015; 61: 464-467.
17. Rajasingham R, Rolfes MA, Birkenkamp KE et al. Cryptococcal meningitis treatment strategies in resource-limited settings: a cost-effectiveness analysis. PLoS Med 2012; 9: e1001316.